Evotec receives US$ 2.5 m grant to leverage human iPSC-derived teratogenicity platform for global health programmes

  • Evotec SE announced today that the Company has received a US$ 2.5 m grant from the Bill & Melinda Gates Foundation (“the foundation”) for its teratogenicity platform, and joins the foundation’s prestigious Global Health Discovery Collaboratory (“GHDC”), a network of researchers, centres of excellence, and technology platforms working together to accelerate the discovery and translation of global health interventions. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-us-25-m-grant-to-leverage-human-ipsc-derived-teratogenicity-platform-for-global-health-programmes-6356

    Du magst vielleicht auch